Amendment 001.pdf

AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT

1. CONTRACT ID CODE

PAGE OF PAGES

1 1

2.AMENDMENT/MODIFICATION NO.

3. EFFECTIVE DATE

08/10/2021

4. REQUISITION / PURCHASE REQ. NO.

2315/Pittman

PROJECT NO. (If Applicable)

6. ISSUED BY

Federal Bureau of Prisons Residential Reentry Contracting 200 Chestnut Street US Customs Building, 7th Floor Philadelphia, PA 19106

CODE 7. ADMINISTERED BY (If other than Item 6)

CODE

8. NAME AND ADDRESS OF CONTRACTOR (No., street, county, State and ZIP Code)

X 9A. AMENDMENT OF SOLICITATION NO

15BRRC21R000000349

X 9B. DATED (See Item 11)

07/26/2021

10A. MODIFICATION OF CONTRACT/ORDER NO.

CODE FACILITY CODE 10B. DATED (See Item 13)

11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS

[ X ] The above number solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offers [ X ] is extended, [ ] is not extended.

Offers must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended, by one of the following methods.

(a) By completing Items 8 and 15, and returning 1 copy of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted; or (c)By separate letter or telegram which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by telegram or letter, provided each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.

12. ACCOUNTING AND APPROPRIATION DATA (If required)

13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OR CONTRACTS/ORDERS,

IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.

A. THE CHANGE ORDER IS ISSUED PURSUANT TO: (Specify Authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.

B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation data, etc.) SET FORTH IN

ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b).

C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:

D. OTHER (Specify type of modification and authority)

E. IMPORTANT: Contractor [ ] is not [ X ]is required to sign this document and return 1 copies to the issuing office.

14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible).

Solicitation 15BRRC21R00000349 is hereby amended as follows:

1) Change Section F.2 (a): The Contractor’s facility must be fully operational and ready for performance to begin within 180 days after the date of contract award.

2) Change Section L.5 (j) to read: Contract performance will be 180 days after the date of contract award, unless otherwise specified by the Contracting Officer.

3) Change Section M.4 (2.4)(3) to read: the soundness and credibility of the offeror’s plan for ensuring operational availability within 180 days after contract award.

4) Change all references in the Compliance Matrix from 120 days to 180 days.

5) Replace the current Attachment H of the Statement of Work with the revised version of Attachment H (attached).

6) Change the closing date from August 26, 2021 to September 17, 2021.

Except as provided herein, all items and conditions of the document referenced in item 9A or 10A, as heretofore changed, remains unchanged and in full force and effect.

15A. NAME AND TITLE OF SIGNER (Type or print)

16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print)

15B. CONTRACTOR/OFFEROR

(Signature of person authorized to sign)

15C. DATE SIGNED 16B. UNITED STATES OF AMERICA

BY

(Signature of Contracting Officer)

16C. DATE

SIGNED

NSN 7540-01-152-8070 30-105 STANDARD FORM 30 (REV. 10-83)

PREVIOUS EDITION UNUSABLE Prescribed by GSA

Attachment H

URINALYSIS PROCEDURES

URINALYSIS TESTING SPECIFICATIONS

The laboratory must comply with all specifications contained herein and all applicable local, state, and federal law, as indicated in 42 CFR Part 493.

Urine samples submitted for testing will contain the laboratory’s required minimum amount of urine, ordinarily 25 milliliters.

If necessary because of litigation, the laboratory must provide a qualified expert witness to testify as to laboratory procedures employed as well as to accuracy and reliability of test results. Additionally, the laboratory must be able to prove chain of custody.

The laboratory is required to demonstrate a satisfactory intrinsic quality control program and to participate in at least one proficiency testing program which is conducted by local, state, or federal agencies, or professional groups, and must have demonstrated satisfactory performance in that proficiency testing program for at least the last two years. The laboratory will provide results of proficiency testing to the contractor, at least annually. RRMs will review these findings during monitoring visits.

Specifications of Methodology Sensitivity - The laboratory will have the capability to detect and identify certain drugs and metabolites by basic screen at minimal levels, or lower, as indicated in the PRIMARY TEST

PANEL.

Basic Screening Procedures - All primary initial screen tests will be by Department Health and Human Services (DHHS) certified Enzyme Multiplied Immunoassay Technique (EMIT)or other DHHS certified comparable testing technology (CERT) as indicated, with the SPECIAL test initial screen being EMIT/CERT as indicated under the SPECIAL test group. All testing will be performed according to manufactures specifications for all requests and instruments, as in FDA approved package inserts or appropriate manufacturer accreditation body which has reviewed and accepted the laboratories modified protocol.

Confirmation of Positive Tests - The approved methods of confirmation of specimens testing positive are listed in both the Primary and SPECIAL test panels above. Confirmation tests must be done on all initial positives. The confirmation testing shall be capable of providing levels as specified in the chart outlined in this attachment. Examples of scientifically recognized DHHS methods of testing are gas chromatography/mass spectrometry (GC/MS), gas chromatography/tandem mass spectrometry (GC/MS/MS), two dimensional gas chromatography/mass spectrometry (GC/GC/MS) or LC/tandem mass spectrometry (LC-MS/MS). No substitutions can be made to the methods. The positive rate of all samples is estimated to be between six percent and seven percent.

Other Requirements - The laboratory must perform the test within 48 hours of receipt. The laboratory will telephonically notify the contractor facility of positive results within 24 hours of the time the test was performed.

Urine specimens testing positive must be retained by the laboratory for minimum of 30 days for possible retesting, if requested.

STANDARD PROCEDURES FOR COLLECTING URINE SURVEILLANCE SAMPLES

1. To the extent possible, urine samples should be collected in one or two specific centralized and suitably equipped locations within the facility, by contract staff who are thoroughly familiar with the procedures specified below.

2. Residents will be thoroughly searched to detect any device designed to provide a urine substitute or possible contaminant and will thoroughly wash their hands prior to providing the sample.

3. When the resident reports for testing contract staff will:

● Make a positive picture identification of the resident;

● Collect the sample from the resident;

● Assign the sample a urine sample identification number;

● Label the urine container with that number and the date; and

● Record the number next to the resident's name on the lab slip.

4. Bottles will be kept under direct contract staff observation and control at all times, both before and after the resident furnishes the urine sample.

5. Two report form lines are provided for each urine sample on the lab form. Ordinarily, to be submitted for testing, bottles will be full (i.e., 60cc or 2 oz.). Once a sufficient sample is provided, contract staff will ensure that the urine sample identification number on the bottle corresponds to the number assigned to that resident on the lab slip. Contract staff will then document this verification by initialing the lab slip entry for that resident. Until the lab form is revised to provide a column specifically for initials, initials should be placed in the right most portion of the medication column.

6. The resident will then be asked to verify the numbers on the bottle and the lab slip and to initial the lab slip to indicate his/her verification. A cover sheet should be used which will permit the resident to view only his/her entries on the lab slip. If the resident refuses, a second contract staff member should make this verification and initial the form.

7. After samples are collected they will be maintained under direct contract staff observation until moved to a locked area where they may be stored until mailing. This area should be designated by the Urine Facility Director and will be accessible to a very limited number of contract staff. Under no circumstances will residents have access to this area.

8. All samples will be mailed to the testing laboratory no later than 24 hours after collection, (excluding holidays and weekends).

9. When a positive result is received, and an incident report written, a photocopy of both the slip returned by the lab and the slip listing the resident's name and urine sample identification number (retained at the facility) will be attached to the incident report and made a part of the disciplinary record. Other resident names will be blocked out of the photocopy.

DETECTION PERIODS FOR SELECTED DRUGS

The time periods below are estimates of the maximum lengths of time, after last use, that a person's urine would be positive for a particular drug. These periods also represent the minimum waiting periods between samples on which successive disciplinary actions for the same drug ordinarily may be based. For example, ordinarily at least 30 days must elapse between urine collection dates before disciplinary action may be taken for a second THC positive. The resident could, however, be retested within this 30 day period and disciplinary action could be based on positive results for drugs other than THC.

3 days Amphetamines, Methamphetamine, Cocaine, Cocaine

Metabolite, Buprenorphine, Fentanyl, K2Spice (Synthetic Marijuana), MDPV (Bath Salts)

5 days Methadone and Methadone Metabolite

6 days Morphine, Codeine, Opiates, Meperidine (Demerol), Pentazocine (Talwin), Propoxyphene (Darvon), Benzodiazepines, Ecstasy (MDMA), Oxycodone

11 days Barbiturates and Phencyclidine (PCP) 14 days Phenobarbital 30 days THC

Drug/Substance Screening Method

Cut-Off Level

Confirmation Method

Cut-Off Level

Amphetamines EMIT/CERT 300 ng/ml GS/MS or

LC-MS/MS

75 ng/ml

Barbiturates (Amorbarbital, Butabarbital, Butalbital, Pentobarbital, Phenobarbital, Secobarbital)

EMIT/CERT 200 ng/ml GS/MS or

LC-MS/MS

50 ng/ml

Benzodiazepines (Alprazolam)

EMIT/CERT 300 ng/ml GS/MS or

LC-MS/MS

25 ng/ml

Cocaine (Benzoylecgonine)

EMIT/CERT 150 ng/ml GS/MS or

LC-MS/MS

12 ng/ml

THC

(Tetrahydrocannabinol)

EMIT/CERT 15 ng/ml GS/MS or

LC-MS/MS

4 ng/ml

Methamphetamines EMIT/CERT 300 ng/ml GS/MS or

LC-MS/MS

75 ng/ml

Morphine EMIT/CERT 300 ng/ml GS/MS or

LC-MS/MS

25 ng/ml

Oxycodone (Oxymorphone)

EMIT/CERT 300 ng/ml GS/MS or

4LC-MS/MS

25 ng/ml

Opiates

(Codeine, Hydrocodone, Hydromorphone)

EMIT/CERT 300 ng/ml GS/MS or

LC-MS/MS

25 ng/ml

PCP

(Phencyclidine)

EMIT/CERT 100 ng/ml GS/MS or

LC-MS/MS

10 ng/ml

MDPV

(Bath Salts) EMIT/CERT 15 ng/ml GS/MS or

LC-MS/MS

9 ng/ml

Fentanyl

(Nor-Fentanyl) EMIT/CERT 2 ng/ml GS/MS or

LC-MS/MS

1 ng/ml

Synthetic Cannabinoids

(K2/SPICE)

EMIT/CERT 15 ng/ml GS/MS or

LC-MS/MS

LOD

Buprenorphine (Nor-Buprenorphine)

EMIT/CERT 5 ng/ml GS/MS or

LC-MS/MS

4 ng/ml